From professional translators, enterprises, web pages and freely available translation repositories.
masitinib
mazitinibs
Last Update: 2014-11-21
Usage Frequency: 2
Quality:
masitinib 150 mg
masitinibs 150 mg
Last Update: 2017-04-26
Usage Frequency: 6
Quality:
masitinib 150 mg colourants (e171, e 110)
masitinibs 150 mg krāsvielas (e 171, e 110)
Last Update: 2012-04-10
Usage Frequency: 4
Quality:
masitinib is metabolised predominantly by n-dealkylation.
masitinibs tiek metabolizēts galvenokārt ar n-dealkilēšanu.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
masivet 150 mg film-coated tablets for dogs masitinib
masivet 150 mg apvalkotās tabletes suņiem masitinib
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
masitinib is approximately 93 % bound to plasma proteins.
aptuveni 93 % masitiniba saistās ar plazmas proteīniem.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
masitinib 150 mg (equivalent to masitinib mesylate 178.9 mg)
150 mg masitiniba (ekvivalents 178, 9 mg masitiniba mezilāta).
Last Update: 2012-04-10
Usage Frequency: 2
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
people with known hypersensitivity to masitinib should not handle the product.
cilvēki, kuriem ir zināma paaugstināta jutība pret masitinibu, nedrīkst rīkoties ar šīm zālēm.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
repeated dermal contact with masitinib may impair female fertility and foetal development.
atkārtots masitiniba kontakts ar ādu var vājināt sieviešu auglību un augļa attīstību.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
each tablet contains either 50mg or 150 mg of masitinib, which is the active substance.
katra tablete satur 50 mg vai 150 mg masitiniba, kas ir aktīvā viela.
Last Update: 2017-04-26
Usage Frequency: 2
Quality:
to date, other potential risks associated with long-term treatment with masitinib are unknown
līdz šim nav zināmi citi iespējamie riski, kas saistīti ar ilgtermiņa ārstēšanu ar masitinibu
Last Update: 2015-07-30
Usage Frequency: 1
Quality:
Reference:
masivet contains masitinib, which belongs to a class of medicines having an anticancer action.
masivet satur mazitinibu, kas pieder pie zāļu grupas ar pretvēža iedarbību.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
has an allergic reaction to masitinib, the active ingredient of masivet or an excipient used in this medicine.
sunim ir alerģiska reakcija uz masitinibu, kas ir masivet aktīvā sastāvdaļa, vai uz kādu no palīgvielām, kas lietotas šajās zālēs.
Last Update: 2012-04-10
Usage Frequency: 1
Quality:
Reference:
concurrent use of other substances with a high degree of protein binding may compete with masitinib binding and thus cause adverse effects.
vienlaicīga citu vielu lietošana, kuras stingrāk saistās ar proteīniem, var radīt konkurenci masitiniba saistīšanai un tādā veidā izraisīt nevēlamus efektus.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
it should not be used in dogs that may be hypersensitive (allergic) to masitinib or any of the other ingredients.
to nedrīkst lietot suņiem, kam ir paaugstināta jutība (alerģija) pret mazitinibu vai kādu citu šo zāļu sastāvdaļu.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
response to treatment with masitinib was expressed as stable disease; i.e. static, partial or complete response.
reakcija uz ārstēšanu ar masitinibu izpaudās kā stabila slimība, t.i., statiska, daļēja vai pilnīga reakcija.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
masitinib treatment should only be used in dogs with non-resectable mast cell tumours and which express the mutated c-kit tyrosine kinase receptor.
Ārstēšanu ar masitinibu drīkst lietot tikai suņiem ar neoperējamiem tuklo šūnu audzējiem, kuri ekspresē mutējušu c-kit tirozīna kināzes receptoru.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
masitinib treatment should only be used in dogs with non-resectable mast cell tumours, which express the mutated c-kit tyrosine kinase receptor.
Ārstēšanu ar masitinibu drīkst lietot tikai suņiem ar neoperējamiem tuklo šūnu audzējiem, kuri ekspresē mutējušu c-kit tirozīna kināzes receptoru.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference:
masitinib 50 mg (equivalent to masitinib mesylate 59.6 mg) masitinib 150 mg (equivalent to masitinib mesylate 178.9 mg)
50 mg masitiniba (kas atbilst 59,6 mg masitiniba mezilāta) 150 mg masitiniba (kas atbilst 178,9 mg masitiniba mezilāta)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Reference:
overdosing signs were observed in toxicity studies conducted in healthy dogs, treated for 39 weeks at doses of around 2 times the recommended dose (25 mg masitinib), treated for 13 weeks and 4 weeks at doses of around 3 times the recommended dose (41.7 mg masitinib), and treated for 4 weeks at doses of around 10 times the recommended dose (125 mg masitinib).
pārdozēšanas pazīmes novēroja toksicitātes pētījumos ar veseliem suņiem, kuri 39 nedēļas saņēma devu, kas aptuveni 2 reizes pārsniedza ieteicamo devu (25 mg masitiniba), kuri 13 nedēļas un 4 nedēļas saņēma aptuveni 3 reizes augstāku devu nekā ieteicamā deva (41,7 mg masitiniba), un kuri 4 nedēļas saņēma aptuveni 10 reizes augstāku devu nekā ieteicamā deva (125 mg masitiniba).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
Reference: